1. Bydureon [Prescribing information] San Diego, CA: Amylin Pharmaceuticals, Inc; March 2015.
2. Byetta [Prescribing information] San Diego, CA: Amylin Pharmaceuticals, Inc; February 2015.
3. Symlin. [Prescribing information] Wilmington, DE:, AstraZeneca Pharmaceuticals, LP; June 2014.
4. Tanzeum [Prescribing information] Wilmington, DE: GlaxoSmithKline; May 2015.
5. Trulicity [Prescribing information] Indianapolis, IN: Eli Lilly and Company, Inc; March 2015.
6. Victoza [Prescribing information] Princeton, NJ: Novo Nordisk Inc March 2015.
7. Inzucchi, SE, Bergenstal, RM, Buse, JB, et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140149 | DOI: 10.2337/dc14-2441 Available at:
http://care.diabetesjournals.org/content/38/1/140.full.pdf+html. Accessed July 1, 2015.
9. Nathan DM, et al. Medical management of hyperglycemia in type 2 diabetes: A Consensus algorithm for the initiation and adjustment of therapy-A consensus statement from the ADA and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2009 (32): 193-203.
10. Shwartz S, Sievers R, Strange P, et al. Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost analysis. Daibetes Care. 2003;26(8):2238-43.
11. Riddle MC, Rosenstock J, Gerich J, et al. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26(11):3080-6.
12. Aljabri K, Kozak SE, Thompson DM. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial. Am J Med. 2004;116(4):230-5.
13. Malone JK, Beattie SD, Campaigne BN, et al. Therapy after single oral agent failure: adding a second oral agent or an insulin mixture? Diabetes Res Clin Pract. 2003;62(3):187-95.
14. Chow CC, Tsang LW, Soresen JP, et al. Comparison of insulin with or swithout continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients. Diabetes Care. 1995;18(3) 307-14.
15. Trischitta V, Italia S, Mazzarino S, et al. Comparison of combined therapies in treatment of a secondary failure to glyburide. Diabetes Care. 1992;15(4):539-42.
16. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group: Effects of intensive glucose lowering in type 2 diabetes.N Engl J Med. 358:25452559, 2008.
17. The ADVANCE Collaborative Group: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.N Engl J Med. 358:25602572, 2008.
18. Abraira C, Duckworth WC, Moritz T: Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial (VADT): an interim report. Diabetes Obes Metab. 29 July 2008 [Epub ahead of print].
19. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2008;31:111.
20. Rodbard, H., Jellinger, P., et al (2009). Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control. Endocrine Practice, 15(6), 540-559.
21. MicromedexR Healthcare Series [Internet Database]. Greenwood Village, Colo: Thomson Healthcare. Updated periodically. July 1, 2015.
22. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2008 ; 31(Suppl 1:S12-S54.
23. The American Association of Clinical Endocrinologists (AACE) medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan. Endocrine Practice. 2011;17 (suppl 2).
24. Buse J, Weyer C, Maggs D, et al. Amylin Replacement with Pramlintide in Type 1 and Type 2 Diabetes: A Physiological Approach to Overcome Barriers With Insulin Therapy. Clinical Diabetes. 20(3):137-144.
25. Hollander PA, Levy P, Fineman MS, et al. Pramlintide as an adjunct to insulin therapy Improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care. 2003 Mar;26(3):784-790.
26. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003 Mar;26(3):881-885.
27. Ratner RE, Dickey R, Fineman M, et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med. 2004 Nov;21(11):1204-1212.
28. Ratner RE, Want LL, Fineman MS et al. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther. 2002;4:51-61.
29. Whitehouse F, Kruger DF, Fineman M, et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care. 2002;25:724-730.